About Us

The vision of EMJ & American Medical Journal is to elevate the quality of healthcare globally, and to improve patient outcomes. We do this across 18 therapy areas and the pharmaceutical sector via EMJ GOLD. We use industry-leading digital tools, to meet the challenges of time-poor medical professionals with a real passion to learn. 

Founded in 2012, EMJ is the go-to place for open access education and lifelong learning opportunities, that builds trust between healthcare professionals and Pharma, to help them continuously improve together. 

American Medical Journal (AMJ), was founded in 2024 building on the success of our partner publisher, EMJ, to better meet the needs of healthcare professionals in the United States. The American Medical Journal delivers high-quality, tailored content across 6 key therapy areas designed to support and enhance clinical practice for our U.S.-based audience. At the core of our content community is a portfolio of peer-reviewed, open-access journals, which are complemented by alternative formats such as podcasts, webinars, videos, and infographics. These provide an essential resource for senior medical professionals today and the brilliant new minds of tomorrow. 

Our in-house Medical Writers and Editors at EMJ and American Medical Journal are supported by top opinion leaders and experts from our renowned Editorial Boards. We take pride in ensuring that our content undergoes peer review and quality controls of the highest standards. We continuously monitor the quality of our contributors and content very closely, through our unique EQOH Score. 

We have built our incredible team by recruiting on values. We stay true to these values in everything we do, as we remain steadfast in our goal to create Gold Medal Winners. 

For trusted partners looking to share our vision, we have one of the best content hubs around, producing exceptional content that helps HCPs and Pharma achieve their common goals. 

If you have a medical advancement that is destined to improve patient outcomes, we’d love to hear from you.